Cinacalcet

Overview

4.6 out of 5 (24 Reviews)

Credits

1.00

Post Assessment Questions

5

Start Date

1 Jan 2021

Last Review Date

24 Feb 2024

Expiration Date

31 Dec 2023

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Cinacalcet hydrochloride is classified as a calcimimetic medication approved by the US Food and Drug Administration (FDA) for the management of secondary hyperparathyroidism associated with end-stage kidney disease and primary hyperparathyroidism in cases where surgical intervention is not feasible. Cinacalcet is also used off-label for the treatment of calciphylaxis in patients with advanced kidney disease or undergoing dialysis.

Cinacalcet's primary indication is to lower the parathyroid hormone (PTH) levels in patients with secondary hyperparathyroidism associated with end-stage kidney disease. Cinacalcet is crucial in treating chronic kidney disease (CKD) by decreasing serum PTH levels and preventing bone deterioration in patients who frequently experience elevated phosphorus and PTH levels and fluctuating calcium levels. Cinacalcet can be utilized for treating primary hyperparathyroidism in individuals who are not suitable candidates for surgery or for whom surgery poses a high risk. By lowering PTH and serum calcium levels, cinacalcet can be combined with bisphosphonates to diminish calcium resorption from bone. Cinacalcet is often used off-label as a treatment regimen for individuals with calciphylaxis—a condition that can occur in patients with end-stage kidney disease.

This activity reviews the indications, mechanism of action, adverse event profile, and other relevant interactions of cinacalcet pertinent to interprofessional healthcare team members involved in treating patients with hyperparathyroidism and related conditions. This activity allows healthcare professionals to customize treatment strategies tailored to each patient's needs by making well-informed decisions, optimizing dosage regimens, and minimizing the risk of adverse reactions, thereby delivering precise and personalized care and improving patient outcomes.


Target Audience

This activity has been designed to meet the educational needs of physicians.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify patients with secondary hyperparathyroidism associated with end-stage kidney disease who may benefit from cinacalcet therapy based on clinical presentation, laboratory results, and treatment history.

  • Implement cinacalcet therapy effectively by establishing appropriate dosing regimens and considering patient-specific factors such as kidney function, concurrent medications, and potential drug interactions.

  • Apply evidence-based guidelines and clinical knowledge to select optimal treatment strategies incorporating cinacalcet for patients with hyperparathyroidism, ensuring individualized care plans.

  • Collaborate with interprofessional healthcare team members to coordinate comprehensive care for patients receiving cinacalcet, optimizing treatment outcomes.

Disclosures

The Campbell University Jerry M. Wallace School of Osteopathic Medicine (CUSOM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they or their immediate family may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CUSOM for resolution, to ensure fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

CUSOM will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for authors, editors, planners, peer reviewers, and/or relevant staff is provided with this activity.

Continuing Education Accreditation Information

 

 

The Campbell University Jerry M. Wallace School of Osteopathic Medicine (CUSOM) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. CUSOM designates this enduring material for a maximum of 1.00 AOA Category 1 B Credits and will report CME credits commensurate with the extent of the physician's participation in the activity.

Cancellation Policy: Cancellations must be received in writing and a money back guarantee is provided if not completely satisfied.

  • StatPearls and CUSOM reserve the right to cancel any course due to unforeseen circumstances. StatPearls and CUSOM will not be responsible for other expenses incurred by the participant in the unlikely event that the program is canceled.

Equal Opportunity

  • StatPearls and CUSOM are Equal Opportunity / Affirmative Action / Equal Access Institutions. 

Medium or Media Used:

  • Computer Requirements:  Internet Access
  • E-mail Address

Instructions for Credit

  1. Register for the activity and create a StatPearls login.     
  2. Review the required accreditation information:  Target audience, learning objectives and disclosure information.
  3. Complete the entire self-study activity.
  4. Complete the post-test assessments.
  5. Successfully pass the post-test with a minimum score of 100%.
  6. Complete the evaluation form.
  7. Obtain a certificate.

StatPearls and CUSOM adheres to AOA Standards regarding commercial support of continuing medical education. It is the policy of StatPearls and Campbell that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that authors and editors will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made prior to starting the activity.

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

This course is intended for osteopathic physicians who wish to earn AOA CME credit. Take this version of the course to ensure you receive appropriate credit.

 

 
 

Reviews

edwina w. on 9/4/2021

Gibi G. on 11/3/2021

Frederick a. on 3/7/2022

Manish Kumar S. on 5/25/2022

K.Navanitha R. on 7/13/2022

Susan G. on 9/9/2022

Toni-Marie P. on 9/29/2022

Lauren K. on 11/29/2022

Kriti M. on 12/22/2022

Rakesh M. on 6/8/2023

Brianna L. on 6/19/2023

Michael S. on 8/24/2023

Janet B. on 8/25/2023

Anuradha S. on 9/18/2023

Ashok V. on 11/7/2023

Michael H. on 12/15/2023

Wassim E. on 12/17/2023

ROBERT Z. on 12/25/2023

BLAKE W. on 1/24/2024

Anuradha S. on 2/4/2024

Redentor R. on 2/29/2024

Julia B. on 3/5/2024

Derrick R. on 3/7/2024

Lance F. on 4/17/2024

Unlimited Physician CME

Stay up to date on the latest medical knowledge with 6673 CME activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7923.5 hours of CME.

Learn About Lifetime CME

Single Activity

Take this single activity

$39 1 activity

6 Month Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$399 per half year per user

1 Year Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$599 per 1 year per user